64 MDCT
TOSHIBA 1.5 T MRI EXCELART Vantage XGV F2-Edition Ver.8.02
CTL array coil
4 ( 29.8 ) true SSFP 3D-FE_fc 2
flip angle (FA) 10 60
10 coronal
true SSFP FA
TR:14.7 ms TE:7.2 ms 2.0 mm matrix 224 224 field of view (FOV) 30 30 cm
2 CHESS
244 Hz/pixel 25
2 min 58 s
3D-FE_fc FA
TR:34.8ms TE:10ms 2.0 mm matrix 224 224 field of view (FOV) 30 30 cm
s
5 ROI
1 ROI
16 pixel
=|(SIT SIBG) / (SIT+SIBG)/2
SIT SIBG
8 ROI
ROI 16 pixel
true SSFP
2 3D-FE_fc 3 true SSFP FA
FA
FA 3D-FE_fc
FA=10 30
FA
4 true SSFP
FA
3D-FE_fc FA
true SSFP
5 6 true
SSFP FA
FA 30
3D-FE_fc FA
FA=40 FA
1 ROI
5 ROI
2 true SSFP FA
3 3D-FE_fc FA
true SSFP
FA FA
FA FA
A
C D
3D-FE_fc
FA FA
A B
C D
4 true SSFP 3D-FE_fc FA
5 true SSFP FA
ROI
true SSFP
true SSFP
6 3D-FE_fc FA
MRI
MRI
5~7)
true SSFP 3D-FE_fc 2
3D-FE_fc FA=10
3D-FE_fc FA
true SSFP heavy T2
2 true SSFP
3D-FE_fc
3D-FE_fc MR-myelography MRI
far-out syndrome
FE3D_fc
1) MRI
MR 61(1):83-86,2010
2)
balanced sequence MRI MR myelography 21(2) 123-128, 2008
3) Ross JS. Newer sequence for spinal MR imaging smorgasboad or succotash of acronysm?.
AJNR Am J Neuroradiol 20(3) 361-373, 1999 4)
revision 22(7) 835-839, 2009
5)
52(9) 1071-1076, 2009 6)
3 MRI 21(2) 115-121, 2008
7) Far-out
syndrome 52(9)
1081-1087, 2009 8)
23(5) 515-520, 2010
1) 1) 2) 1) 1)
1) 1) 1) 3)
1 2
3
( )
4 4
7
4 130ml
14 276ml
2010 8 ERBE
VIO300D
VIO300D
200V
100
1-3)
1)
1)
VIO300D
4)
25-30
1 8
5 10
5mm 10mm 5
2
25 1 4
7 4 8
1
1
2
3
2
3
1
1 (
)
3,500 4,300V
1
5 10
2
5mm (
5mm 10mm )
70
10mm( 20mm) 40
4 10 16mm( 8mm)
10mm 40
2mm 3
2 3
2
4 130ml (80,100,220,100ml)
1)
5 10
4 4
4 4
1,2)
2) 5mm
2 3mm
6 8
8 10mm 6 8 8
130ml 14
4) 276ml(80-500)
1
7
1
2012, 27-35,
2 VIO IO
2009, 1-7, , 2009 3
. 65: 1498-1503 2010 4
-1: 35-37 2012
1 2 2 1 3 1
1 2 3
2012
30 1
2010
2010 1 8.9 2013 1 26.7
2012 1 12 2600
Key Words
2007 2012
30
1
2010 1 8.9
2)
1
2
3 1
2010
1 8.9 2013 1
26.7 2 2012
1 12 2600
2010 2011
2012 1 13.2
2012 172
2013 1 26.7
4
4 2012 6 12
180
2012 6
2012
11 39
2012 1 13.2 26.7
2012 4 100 7
50 11 60
2013
26.7% 1
2600
1
(Vol.52 No.10):19(1443)-26(1450),2010.9
2
,5-14,2010.3
2
3
1
2
5 10 15 20 25 30
20110 1 2013 1
5-9cm
9 ( 2 :7 )
125ml 4
Key Words Fast-track (ERAS)
2001 Cotton1
Fast-track Kehlet
Enhanced Recovery After Surgery : ERAS
2
4-8)
1 (1)
2 1-2
1 1
10-20
(2)
2 OS-1
(3)
30 2
3
(4)
5-9cm (5)
4 1 4 100m
(8)
1. 0
2 11
2. : 15-16 :
4 11
3. 15 4
18
4. 7
11
1
2
2
125ml
4
( 14-16 15.2 )
2 20
3 1 1
16.0 44.3
3 1 1 n=9
10
74 80
9,10)
11) 2007 4030
2
1
2 90%
5,8)
6
2 12,13)
12)
2 4
9cm
100-200cc 7)
4
14,15)
1 1 1
2 14)
1 1
16 44
4,5,8)
1 Cotton P: Fast-track improves CABG outcomes. JAMA 270: 2023, 1993
2 Wilmore DW, Kehlet H: Management of patients in fast track surgery. BMJ 322, 473-476, 2001
3 , ,
29: 219-226, 2004 4)
. 8: 125-132, 2006
5)
. 10: 111-114, 2008
6) , DPC
. 14: 22-25,2012
7)
1:35-37, 2012
8) :
14:215-217,2012 9) Kirsh E J, Worwag E M, Sinner M et al: Using outcome data and patient satisfaction surveys to develop policies regarding minimum length of hospitalization after radical prostatectomy.
Urology 56:101 107, 2000
10) Worwag E, Chodak GW : Overnight hospitalization after radical prostatectomy: the impact of two clinical pathways on patient satisfaction, length of hospitalization, and morbidity. Anesth Analg 87:62 67, 1998
11) , ,
. 102: 713-720, 2011
12)
.
http://www.anesth.or.jp/guide/index.html
13) Lobo DN, Hendry PO, Rodrigues G, et al:
magnetic resonance imaging in healthy adult volunteers a randomised double-blind, crossover study. Clin Nutr 28, 636-641, 2009
14) , ,
(Enhanced Recovery After Surgery:ERAS)
. 64, 214-223,
2011
15) Kehlet H, Mogensen T Hospital stay of 2 days after open sigmoidectomy with a multimodal rehabilitation program. Br J Surg 86 227-230, 1999
CT Colonography
CT CT Colonography CTC
2011
CTC 2011 2 1 2012 1 31 CTC
21 CTC
CTC 10.2 1 31 CT 9 7
4 21
CTC
Key Words CTC
CT Colonography CTC CT
3
CT CT Colonography CTC
1 3 CTC
4 3D
navigation 2011
CTC CTC
room air
CT CT
0.5mm
64 CT
Aquilion TSX 101A 1
3 AZE
Virtual Place
2
72.5 51 87
13 8 16
3 2
CTC
10.2 1 31 CT 9
1 CTC
1
room air
2
2
F T
M A
F Ra
M A
M S
M Ra a
F A
F A a
M C
F D
M S
F A
M D
M Rs a
M A C
M C,S
F D
M S
M D
M Rs
F Rb a
1
2
3
4
5
6
16 2
78 TCF
1 fiber
S 3
4 CT CT
3
S 3
S
CT PET
CTC CT
3
5
6
CTC
CTC CT
CTC
navigation
7 8
CTC
CTC
CTC 21
CT
CT
4
room air
30
CTC
3
CTC
1 Pickhardt PJ Taylor AJ Kim DH et al.
Screening for colorectal neoplasia with CT colonograhpy. Radiology 224 393 403 2002
2 CT colonography
. Rad Fan 9 27 30 2011
3 CT
108 899 907 2011
4
CT 47 34 45 2012
helical CT and virtual reality AJR 162(suppl) S104 1994
6 CT Colonography
INNERVISION 25 32 34 2010
7 Matsuki M Okuda J Kanazawa S et al Virtual CT colectomy by three-dimensional imaging using multidetector-row CT for laparoscopic colorectal surgery Abdom Imaging 30 698 708 2005
8
CT Colonography
Virtual CT Laparoscopy INNERVISION 25 35 37 2010
3 16
3
58-91 ( 76.6 ) 12 GnRH
LH 1
2 50ng/dl LH 1
1 0.1 1.0mIU/ml 1
1 1 LH 0.1mIU/ml
66.6 41.6 33.3
GnRH GnRH 1 1 LH 0.2
5.3 mIU/ml 0.3 mIU/ml 1 1.2 mIU/ml
LH GnRH
1
Key Words GnRH LH
1941 Huggins Hodges
,
1)
GnRH , GnRH
, GnRH
LH ,
GnRH
LH GnRH 80mg 120mg
120mg 2 ,2
80mg 1 ,
GnRH 2
GnRH 58-91
( 76.6 ) 12
GnRH
LH CLIA
2.GnRH GnRH
1 LH
1.GnRH LH
1 1 GnRH
1 100ng/dl
2 50ng/dl
2 50ng/dl
4 3 (224.6ng/dl) 1 (59.9ng/dl) 9 1 (75.7ng/dl)
2 2 GnRH LH
LH 1
1
0.1 1.0mIU/ml
, , ,
, ,
66.6 41.6
33.3 16.7
2.GnRH GnRH
1 LH
( 3)
GnRH 1 LH 0.2 5.3
mIU/ml 3 0.7
mIU/ml 1 0.3 mIU/ml
GnRH 1 LH
1.2 mIU/ml 19.4ng/dl
GnRH
GnRH GnRH
14 2
15%
GnRH
2,5) 1
100ng/dl
2 50ng/dl
4 1
59.9ng/dl
1 LH 0.1mIU/ml
GnRH GnRH
GnRH 1
GnRH
3 LA
6
6) GnRH
GnRH
Garnick 7) GnRH Abarelix GnRH
1
GnRH GnRH
1 1 LH
Crawford ED
8)
PSA
GnRH
GnRH
1
1 GnRH
1 GnRH
1 2 3 1 2 1 2 3 4
n 12 6 7 9 8 6 11 10 6 2
382.2 70.9 39.2 55.5 28.9 18.6 22.6 22.1 16.0 27.2 130.8 53.2 25.9 20.6 12.5 5.8 6.4 7.6 6.5 10.0 656.0 98.0 49.4 224.6 75.7 32.9 59.9 48.8 40.1 44.3 159.1 18.2 8.8 64.1 20.0 11.1 14.8 14.4 12.6 24.3
1 10 100 1000
1
2
3
4
5
6
7
8
9
10
11
12
2 GnRH LH
2 GnRH LH
1 2 3 1 2 1 2 3 4
n 12 6 7 9 8 6 11 10 7 2
10.1 1.8 0.7 0.9 0.4 0.2 0.2 0.3 0.3 0.6
0.8 0.4 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.1
32.2 4.1 1.7 2.9 1.2 0.4 1.0 1.0 0.9 1.1
9.0 1.3 0.6 0.8 0.4 0.1 0.3 0.3 0.3 0.7
0.1 1 10 100
1
2
3
4
5
6
7
8
9
10
11
12
3 GnRH GnRH 1 LH
1 Huggins C, Hodges CV.: Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin 22: 232-240,1972
2 OZONO S, UEDA T, HOSHI S, et al: GnRH :
12 II
. Jpn J Clin Oncol 42:
477-484,2012
3 , :
GnRH
5 NEWS GnRH ( )/
( 80mg,120mg)
61: 529-531, 2012
6 :
LHRH
? 56: 301-304, 2010
7 Garnick MB, Mottet N: New treatment paradigm for prostate cancer: abarelix initiation therapy for immediate testosterone suppression followed by a luteinizing hormone-releasing hormone agonist. BJU Int 110: 499-504, 2012 8 Crawford ED, Tombal B, Miller K, et al.: A
0.1 1 10 100 1000
LH R
R
50
1
55 BHL 2
CT BHL
8 X 58%
Key Words
20
67.7% 42.2% X
59.7%
1) BHL
55
37 43
X BHL
36.4 116/57mmHg
80 / SpO2 97%
3.7 % Bas 0.7 % Mon 8.6 % Lym 24.0 % RBC 512 104 Hb 13.9 g/dl Ht 41.3 % MCV 80.7 fl Plt 18.7 104 T-P 7.4 g/dl Alb 4.1 g/dl LDH 232 IU/l CRP 0.1 mg/dl BUN 14.0 mg/dl Cre 0.6 mg/dl Na 140 mEq/l K 4.8 mEq/l Ca 9.6 mEq/l P 4.3 mg/dl
ACE 37.4 U/I CEA 2.5 ng/ml AFP 6.2 ng/ml CYFRA 1.7 ng/ml
X 1 2 X
BHL
CT 2
61/ PR 0.16
QRS 0.8 QTc 0.42 ST-T
FVC 131.1% 1 73.2%
1
2 (BAL)
Fraction1.2 20 15%
CD4/CD8 6.0
BHL
3
8
BHL (
58% :3.6x2.3cm 8 2.3 1.5cm
1 X
BHL 8 BHL
8
2 CT
1
FVC (L) (% pred.) 3.37 (131.1%)
FEV1(L) (% pred.) 2.47 (111.8%)
FEV1/FVC (%) 73.2
FRC (L) (% pred.) 2.23 (128.9%)
RV (L) (% pred.) 1.31 (78.4%)
TLC (L) (% pred.) 4.70 (117.2%)
RV/TLC (%) 27.8
Dlco (ml/min/mmHg) (% pred.) 16.32 (80.1%) DLco/VA (ml/min/mmHg/L) (% pred.) 4.57 (94.2%)
2 BAL
3
raction 1 2 3
Cell count 1.0 1.0 1.0 105cells/ml
Neutrophil 0.0 1.0 8.0 %
Eosinophil 0.0 0.0 1.0 %
Lymphocyte 20.0 15.0 1.0 %
Macrophage 80.0 84.0 90.0 %
CD4/CD8 6.0
5%
47-87%
2 3)
1963 1981 24
5
275 5
X 8%
1) BHL
5 4)
77.6% 83.7%
1)
BHL
5)
4 6
30%
6)
BHL
1) 554 1963 1986
. 25
998-1004 1987 2)
. 60 1794-1800 2002
3)
7 43-50 2003
4) BHL
1 . 12 28-33 2002
5)
Up-to-Date. 12 403-408 2007 6)
. 11
59-62 2005
3
3
2 CT
1 CT
MRI A 2 SAH
Key Words
3
1
47 25
CT
2
MRA 3D-CTA
1A B
1C
33 CTA
1D
2
62 17
CT
3
3D-CTA
pearl and string sign 2A
cervical portion intimal flap 2B
1
A: 1 MRA
B: 2 3D-CTA
C: 14 3D-CTA
D: 33 3D-CTA
A B C D
2
A: 1 3D-CTA pearl and string sign
B: 8 CTA
cervical portion intimal flap
C: 3D-CTA
3 67
MRI
MRA
2
CT
Subarachnoid
hemorrhage SAH 3A B
retrospective MRA
3C
2 SAH
CT SAH
SAH
3
SAH 1
3
A B: CT
C: MRA retrospective
A B C
1
3 3
SAH 3
3
40 50
1)
2)
SAH
3)
3
2
1 2
5)
1
3) 77.8% 80.6%
96.4% 3
SAH 3
1 2 3
47 62 67
1) Mizutani T: Treatment consideration for cerebral dissecting aneurysms based on the pathological mechanism findings and the healing process. Jpn J Neurosurg (Tokyo) 19: 104-111 2010
2) Kurihara T: Headache neck pain and stroke as characteristic manifestations of the cerebral artery dissection. Intern Med 46: 257-258 2007 3) Mizutani T: Natural course of intracranial arterial dissections. J Neurosurg 114: 1037-1044 2011
4) Nakagawa K Touho H Morisato T Osaka Y et al: Long-term follow-up study of unruptured vertebral artery dissection:Clinical outcomes and serial angiographic findings. J Neurosurg 93:
19-25 2000
5) Kai Y Nishi T Watanabe M Morioka M Hirano T et al: Strategy for treating unruptured vertebral artery dissecting aneurysms.
Neurosurgery 69: 1085-1092 2011
1
1 2 3
1 2 3
62 CT
2
3 30mg/
1 11 15 CT
1 11
Key Words chronic subdural hematoma, edoxaban, team medical care
3 3
60 1)2)
11
62
X X
WBC 12800/ l, D-dimer 60.3 g/ml
CT 1A 1B
7
9 8
CT
15
11 13
2 15
CT
3 17
19
43 CT
4 60
1 A:
B:
A B
2
>>
3 15 CT
4 43 CT
t-PA
1)
1 2 /10
70 7.4 /10 3
3
2 20 30
ITP DIC
1) Gentry 2)
CT
CT
CT MRI
1)
3) 4)
Gras J 5) 1 30mg
24
Rust T 7)
42.5
CT
15mg/ 1 11
15 CT
3 3 )
1
CT
1) : . 58: 488-493, 2003
2) Gentry LR, Godersky JC, Thompson B, et al:
Prospective comparative study of intermediate-field MR and CT in the evaluation of closed head trauma. Am J Roentgenol 150:673-682, 1988
3) Delgado-Lopez PD, Martin-Velasco V, Castilla-Diez JM, et al: Dexamethasone treatment in chronic subdural haematoma.
Neurocirugia 20 346-359, 2009
4) Berghauser Pont LM, Dirven CM, Dippel DW, et al: The role of corticosteroids in the management of chronic subdural hematoma: a systematic review. Eur J Neurol. 19: 1397-1403, 2012
5) Gras J: Edoxaban for the prevention of thromboembolic events after surgery. Drugs Today (Barc). 47: 753-761, 2011
6) Saadeh Y, Gohil K, Bill C, et al: Chemical venous thromboembolic prophylaxis is safe and effective for patients with traumatic brain injury when started 24 hours after the absence of hemorrhage progression on head CT. J Trauma AcuteCare Surg 73: 426-430, 2012
7) Rust T, Kiemer N, Erasmus A, et al: Chronic subdural haematomas and anticoagulation or anti-thrombotic therapy. J Clin Neurosci. 13:
823-827, 2006
-2012
-2012
96.3% IPM/CS CAZ
92.6% PIPC AMK TOB LVFX GM 70 1 (3.7%)
MDRP multiple drug resistant 3
2011
1)
2)
2012 9 2013 2 6
198 93
198 47.0 27/198 13.6
1
(%) (S) (S)+ (I)+ (R)
x100
2
96.3% IPM/CS,CAZ 92.6%
PIPC, AMK, TOB LVFX GM 70
MDRP 1 (3.7%)
100ml
H24/ 8 ESBL
MDRP
1
2011
. 1 :50-52, 2012
2
(ESBL ). 1 :4-7,
2012
1
2
2
2009 7
1
2009 7
1 2012
1 Elekt Elekta C
1
2 12 3
ta Syne
CMS X
1 3
ergy Plat Fo XiO
3
orm
2207 239
1
2
( VPN)
( ASP) ID
ID
VPN ASP
2009/7/1 2012/12/31 42
207 239 1
5 3
2
4
( )
1
19-20 JASTRO
22 1 8
JASTRO
1 2009/7/1 2012/12/31
2
3
4
1.
2.
1
(1) (2) (3) (4) (5)
3. A4 1 1 20 20 1 400
Microsoft Word
1 Macintosh
.doc (1) (2)
(3) (4) (5)
4. 1 2
( )
( ) 600 8,000
20 6 3 600 4,000
10 3 3 300 3,000
10 3 2
1,000 2 2
( ) 1 1
( )
3 4 4
et al Medline
,
1. Fuchizaki U, Machi T, Kaneko S: Gastrobronchial fistula. Lancet 24: 1780-1781, 2007
2.
1 . 42: 56-58, 2009
1. p53 20 2001 69-75
( )
( )
mm cm2 mL L dL kg g mg % 5.
3
2
12 19
2
2
2 1
2 2013
926-8605 94
TEL 0767 52-3211 FAX 0767 52-3218 HP http://www.keiju.co.jp Mail [email protected]